Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis

References

• Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technology Assessment 2000; 4(37): 1–191.
   Google Scholar
• Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. Journal of the American Academy of Dermatology 2001; 44 (Supp): S13-S16.
   PubMed Web of Science ®Google Scholar
• Leung D. Atopic dermatitis: New insights and opportunities for therapeutic intervention. Journal of Allergy and Clinical Immunology 2000; 105: 860–876.
   PubMed Web of Science ®Google Scholar
• Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. Journal of the American Academy of Dermatology 2001; 45: 736–743.
   PubMed Web of Science ®Google Scholar
• Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. Journal of the American Academy of Dermatology 2002; 46: 228–241.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Remitz A, Kyllonen H et al. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. American Journal of Clinical Dermatology 2002; 3: 381–388.
   PubMedGoogle Scholar
• Alaiti S, Kang S, Fiedler VC et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. Journal of the American Academy of Dermatology 1998; 38: 69–76.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Ling MR, Langley R et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, Efficacy. Journal of the American Academy of Dermatology 2001; 44 (Supp): S28-S38.
   Web of Science ®Google Scholar
• Paller A, Eichenfield LF, Leung DYM et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology 2001; 44 (Supp): S47-57.
   Web of Science ®Google Scholar
• Kang S, Lucky AW, Pariser D et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Journal of the American Academy of Dermatology 2001; 44 (Supp): S58-S64.
   PubMed Web of Science ®Google Scholar
• Bergman J, Rico MJ. Tacrolimus clinical studies for atopic dermatitis and other conditions. Seminars in Cutaneous Medical Surgery 2001; 20: 250–259.
   Google Scholar
• Rico MJ, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects. Allergy of Asthma Proceedings 2002; 23: 191–197.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Marshall K, Bush C et al. SDZ 981 cream 1% effective in the treatment of pediatric atopic dermatitis patients: two 6- week randomized, double-blind, vehicle- controlled, multicenter studies with 20- week open-label phases. Presented at the 59th annual meeting of the American Academy of Dermatology, 2001, San Francisco, California.
   Google Scholar
• Luger T, van Leent E, Graeber M et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. British Journal of Dermatology 2001; 144: 788–794.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. Journal of the American Academy of Dermatology 2002; 46: 495–504.
   PubMed Web of Science ®Google Scholar
• Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2.
   PubMed Web of Science ®Google Scholar
• Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62: 817–840.
   PubMed Web of Science ®Google Scholar
• Fujisawa Healthcare, Inc. Tacrolimus ointment (Protopic) prescribing information.
   Google Scholar
• Novartis Pharma. Pimecrolimus cream (Elidel) prescribing information.
   Google Scholar
• Lamb SR, Rademaker M. Pharmacoeconomics of drug therapy for atopic dermatitis. Expert Opinions in Pharmacotherapy 2002; 3: 249–255.
   PubMedGoogle Scholar
• Marchetti A, LaPensee K, An P. A pharmacoeconomic analysis of topical therapies for patients with mild-to- moderate stable plaque psoriasis: a US study. Clinical Therapy 1998; 20: 851–869.
   PubMed Web of Science ®Google Scholar
• Ellis C, Drake L, Prendergast M et al. Cost- effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate- to-severe atopic dermatitis. Journal of the American Academy of Dermatology, in press.
   Google Scholar
• Hanifin JM, Thurston M, Omoto M et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Experimental Dermatology 2001; 10: 11–18.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Rustin M, Ruzicka T et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate in adult patients with atopic dermatitis. Journal of Allergy and Clinical Immunology 2002; 109: 547–555.
   PubMed Web of Science ®Google Scholar
• Red Book. Montvale, New Jersey: Medical Economics Company, 2002.
   Google Scholar
• Drake L, Prendergast M, Maher R et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. Journal of the American Academy of Dermatology 2001; 44 (Supp): S65-S72.
   Google Scholar
• Ellis C, Drake L, Prendergast M et al. Cost of atopic dermatitis and eczema in the United States. Journal of the American Academy of Dermatology 2002; 46: 361–370
   PubMed Web of Science ®Google Scholar